Q1 FY 2027 saw record revenue and profit growth, led by a 69% surge in CDMO and 10% rise in Affordable Medicines. Margins expanded, CapEx guidance was raised to meet robust demand, and the business remains diversified with strong outlook for CDMO and Bio segments.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.